Monitor the November 11 earnings call for actual Q3 financials, cash runway update, and clinical milestones for agenT-797. The stock's small market cap ($55M) makes it sensitive to trial readouts and financing updates.
Drug in focus
INKT drug pipeline →agenT-797
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $10.79entry
- T+1 · 13d ago −1.76%α −3.41% · $10.60
- T+5 · 7d ago −7.23%α −6.64% · $10.01
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics announced it will report Q3 2026 financial results on November 11, 2026, before market open. The press release provides no financial data, only a forward-looking update on clinical programs for agenT-797 and strategic collaborations. Consensus estimates are EPS -$0.50 and revenue $875K, but no actual results are disclosed yet.
Key Facts
- Q3 2026 earnings release scheduled for November 11, 2026 before market open
- Conference call and webcast at 8:30 AM ET on November 11, 2026
- No financial results disclosed in this press release
- Consensus estimates: EPS -$0.50, revenue $875K (2 analysts)
- Clinical update highlights: randomized Phase 2 of agenT-797 in acute lung injury, ARPA-H collaboration, SITC 2026 data
- Lead candidate agenT-797 is an off-the-shelf iNKT cell therapy in trials for solid tumors, GvHD, and critical pulmonary immune failure
Financial Impact
No financial data provided in the release; consensus revenue estimate is $875K for Q3 2026
Risk Factors
- No financial data disclosed; actual results may differ from consensus
- Clinical-stage biotech with no approved products; high cash burn risk
- Forward-looking statements subject to risks outlined in SEC filings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393789 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Viewing Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers